Connect Portal

  • Clinical Testing
    • OmniSeq INSIGHT
    • Order Test
    • Specimen Requirements
  • BioPharma Services
  • Publications
  • Patient Support
  • About
    • About
    • Leadership
    • News
    • Careers
    • Forms
    • Contact

Comprehensive genomic and immune profiling (CGIP) treatment patterns and survival in non-small cell lung cancer (NSCLC)

by Christina Black | Oct 18, 2022

Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy

by Christina Black | Sep 1, 2022

Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance

by Christina Black | Jul 28, 2022

LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers

by Christina Black | Jul 28, 2022

Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC

by Christina Black | Jul 28, 2022

« Older Entries

Follow Us on Twitter

Twitter feed is not available at the moment.

  • Facebook
  • Twitter
©2023 OmniSeq Corporation | Privacy Practices and Terms of Use. Regulatory   .